Acute pain is a type of pain that comes on quickly but lasts a short amount of time. Journavx (jor-na-vix) was approved in 2025 and is the first non-opioid medicine in its class that is used to ...

Vertex's medication, named Journavx, is seen as a major development in the ongoing effort to provide effective pain management solutions without the harmful consequences associated with opioid ...

"By managing acute pain effectively, [Journavx] may help prevent the transition to chronic pain, reducing the need for long-term pain management strategies," he added. The drug cannot be used with ...

For decades, Americans struggling with pain had two options to find relief: over-the-counter medication such as ibuprofen, which often provided limited reprieve, or prescription opioids, and the ...

Enter: Journavx, the first pain medication of its ... an anesthesiologist and former director of the pain management division at Hospital for Special Surgery in New York. “It appears to be ...

“With the approval of JOURNAVX, a non-opioid ... we have the opportunity to change the paradigm of acute pain management and establish a new standard of care.” The approval is considered ...

The approval of Journavx, a non-opioid pain medication, could provide a safer alternative for pain management.

Kewalramani cast the moment as an “opportunity to change the paradigm of acute pain management and establish a new standard of care.” Still, Journavx faces some hurdles in winning over ...

Journavx will likely follow the trajectory ... The drug was approved for up to two weeks of pain management. Suzetrigine is a sodium channel blocker that blocks a specific sodium channel called ...

Vertex's Chronic Pain Ambitions Hit Roadblock with LSR Data So much of Journavx's potential lies in chronic pain management. In December, Vertex revealed Phase 2 data evaluating Journavx in ...